Marina Biotech has entered into a binding license agreement with Autotelic Bio for the exclusive development and marketing outside of the United States and Canada of Marina’s IT-103 clinical program.   Under the agreement, Autotelic Bio will obtain a perpetual license to have the right and responsibility to begin clinical development of IT-103 for marketing approval in South Korea and territories outside of United States and Canada.  Through the agreement, Marina will be entitled to the ...